10-K: Skinvisible, Inc. Reports 2024 Annual Results, Cites Progress in Invisicare Licensing and Development

Skinvisible, Inc. files its 10-K for the year ended December 31, 2024, highlighting ongoing efforts to license its Invisicare technology and advancements in clinical trials by its licensee, Quoin Pharmaceuticals.

Summary

• Skinvisible, Inc., a pharmaceutical research and development company, has filed its Form 10-K for the fiscal year ended December 31, 2024.
• The company focuses on its patented Invisicare polymer delivery system and aims to out-license topical skin products globally.
• Skinvisible targets the large skincare, dermatology, and over-the-counter markets, while also exploring opportunities in obesity and other medical markets.
• The company's business model centers on licensing its patented products to established manufacturers and marketers.
• A key license agreement is with Quoin Pharmaceuticals, which is developing products for Netherton Syndrome using Invisicare technology.
• Quoin has made progress in clinical trials, including FDA clearance to recruit teen subjects and international expansion of trials.
• Skinvisible also has a license agreement with Ovation Science for its DermSafe hand sanitizer product.
• The company filed provisional patent applications for transdermal delivery of obesity drugs and glucose-controlling agents.
• Skinvisible faces competition and is subject to government regulations related to cosmetics and skin care products.
• The company's auditors have raised concerns about its ability to continue as a going concern.
• Revenues for 2024 remained at $20,000, the same as in 2023.
• The company recorded a net loss of $565,654 for 2024, compared to a net loss of $2,382,440 in 2023.
• The company has identified a material weakness in its internal controls over financial reporting.
• As of April 10, 2025, Skinvisible had 5,316,843 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's progress in clinical trials and new patent applications, the company's financial situation is precarious, with going concern doubts and a material weakness in internal controls.

Positives

• Quoin's clinical trials for Netherton Syndrome treatment (QRX003) are showing positive initial data and a clean safety profile.
• FDA clearance for Quoin to include teen patients in clinical studies could expedite recruitment and lead to a more robust data set.
• International expansion of Quoin's clinical trials indicates growing interest and potential market reach.
• Filing of provisional patent applications for transdermal delivery of obesity drugs and glucose-controlling agents opens new market opportunities.
• The net loss decreased significantly from 2023 to 2024.

Negatives

• The company has a history of losses and an accumulated deficit of $39,946,142 as of December 31, 2024.
• Auditors have raised substantial doubt about the company's ability to continue as a going concern.
• Revenues remained at $20,000 for both 2024 and 2023.
• The company has identified a material weakness in its internal controls over financial reporting.
• The company relies on third parties to manufacture its products, which subjects it to factors outside of its control.

Risks

• The company's financial status creates doubt about its ability to continue as a going concern.
• Failure to raise additional capital or generate sufficient cash flows could reduce the company's ability to compete successfully.
• The acceptance of the company's products is critical to its success, and there is no guarantee of market demand.
• The company faces competition from companies with greater resources and name recognition.
• Reliance on third-party manufacturers subjects the company to factors outside of its control.
• The company faces inherent risks of exposure to product liability claims.
• Unfavorable publicity within the skin care markets could adversely affect the business.
• International business transactions expose the company to local business risks in different countries.
• The company's commercial success depends on its ability to develop and commercialize products without infringing on the intellectual property rights of third parties.
• The company is highly dependent on its management team and key personnel.
• The company has identified a material weakness in its internal controls over financial reporting.

Future Outlook

The company hopes to generate more revenues from its licenses with Quoin and Ovation in 2025 and plans to enter into commercial arrangements with pharma and biotech companies to exploit its recently filed patent applications.

Management Comments

• Management plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding.
• Management concluded that, as of December 31, 2024, our internal control over financial reporting was not effective.

Industry Context

The company operates in the competitive skincare and pharmaceutical industries, where innovation and effective delivery systems are key. The need for pharmaceutical companies to access external R&D companies for new products due to their own downsizing or elimination of internal R&D departments is a viable model for Skinvisible.

Comparison to Industry Standards

• It's difficult to directly compare Skinvisible's financial performance to industry standards due to its unique business model and small size.
• However, the company's reliance on licensing agreements is a common strategy in the pharmaceutical industry, particularly for smaller companies with innovative technologies.
• Quoin Pharmaceuticals is a key partner, and its progress in clinical trials is crucial for Skinvisible's future revenue potential.
• Companies like Biofrontera and Foamix Pharmaceuticals also focus on dermatology products, but their business models and financial situations may differ significantly.
• The company's focus on transdermal delivery systems aligns with a growing trend in the pharmaceutical industry to improve drug efficacy and reduce side effects.

Related Party Transactions

• On January 31, 2023, the Company negotiated accrued salaries, vacation, and outstanding convertible notes for its two officers.
• Under the terms of the agreements, all outstanding notes totaling $4,220,209, accrued salaries of $1,062,000, accrued vacation of $90,193 were converted to promissory notes convertible into common stock with a warrant feature.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future equity issuances.
• Employees' job security is uncertain given the company's going concern doubts.
• The success of Quoin's clinical trials is crucial for the company's future revenue and potential impact on patients with Netherton Syndrome.

Next Steps

• The company intends to fund operations through increased sales and debt and/or equity financing arrangements.
• The company plans to seek additional financing in a private equity offering to secure funding for operations.
• The company plans to take steps to enhance and improve the design of its internal control over financial reporting during the fiscal year ending December 31, 2025.

Key Dates

Keywords

Invisicare, licensing, Netherton Syndrome, Quoin Pharmaceuticals, transdermal delivery, patent, skincare, pharmaceutical, Skinvisible, OTC